A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
September 15, 2021
End Date
September 30, 2026
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
September 15, 2021
End Date
September 30, 2026